Alchemab Therapeutics Ltd

Alchemab Therapeutics Ltd are delighted to share that its paper titled 'A generative foundation model for antibody sequence understanding' has been accepted for two workshops at the 41st [ICML] Int'l Conference on Machine Learning in Vienna, Austria.   This paper introduces FAbCon, a generative antibody-specific language model comprising 2.4 billion parameters and will be presented as a poster at the workshops on Machine Learning for Life and Material Science (ML4LMS) on July 26th, and Accessible and Efficient Foundation Models for Biological Discovery (AccML) on July 27th.   To read our paper or download our models, use the links in the comments below!

June marks Alzheimer's and Brain Awareness Month and aims to raise awareness and encourage others to take action against #alzheimer’s.   At #Alchemab, we are proud to support this awareness month and strive to provide a new therapy for Alzheimer's for this unmet medical need.   #biotech #lifesciences #antibodies #neuroscience

#Alchemab today announces that it has been awarded a grant of US$595,000 by The Michael J. Fox Foundation for Parkinson's Research (MJFF)!   The grant will fund research performed at Alchemab following its identification of antibodies that target prostaglandin biology in #Parkinsonsdisease, a potentially unique approach to treatment.   Click the link in the comments below to read the press release and learn more about Alchemab's #Parkinsons disease program.   #biotech #lifesciences #antibodies #neuroscience

Meet #Alchemab in San Diego for the BIO International Convention next week!   The event, held from 3-6 June, brings together the full ecosystem of #biotech with more than 18,500 industry leaders from across the globe.   Please get in touch to arrange a meeting in San Diego or to learn more about Alchemab's antibody discovery platform and pipeline of protective therapeutics for hard-to-treat diseases.   #biotech #lifesciences #antibodies #neuroscience   Olivia Cavlan Bill Desmarais Jonathon Marks-Bluth

Great to see the Waltham, MA team at The Boston Home, sharing their passion and work towards addressing neurological disorders! #Alchemab is supporting The Boston Home as its US charity partner for 2024. #HuntingtonsDiseaseAwarenessMonth #Huntingtons #neurologicalresearch

#Alchemab is pleased to announce the publication of its paper, 'A generative foundation model for antibody sequence understanding', in bioRxiv!   The paper details FAbCon, Alchemab's #generative foundation model, demonstrating its suitability to facilitate #antibodyengineering with increasing model scale and extensive evaluations.   The model was trained on NVIDIA’s DGX SuperCloud and Amazon Web Services (AWS) SageMaker.   Read more about Alchemab's model, FAbCon, in the paper linked here: https://bit.ly/3KifrjF   #biotech #lifesciences #antibodies

Meet the #Alchemab team at #DiscoveryEurope2024 for the 5th Annual Neuroscience Drug Development Europe Congress!   Principal Scientist at Alchemab, Paulina Kolasinska-Zwierz is presenting 'A Patient-First Approach To Discovery Of Antibodies Against Neurodegenerative Diseases' on 22nd May at 11:50 CEST.   Hope to see you in Basel for an insightful two-day event on drug development in #neuroscience!   #biotech #lifesciences #antibodies

#Alchemab is joining to raise awareness and understanding of #Huntingtonsdisease this May for Huntington's Disease Awareness Month.   Huntington’s disease is a rare genetic condition for which there is no cure or treatment to slow or stop disease progress, only treatments to help manage the symptoms. It is a devastating neurodegenerative disorder and at Alchemab, we are working towards developing a treatment for this life-changing condition.   #biotech #lifesciences #neuroscience #antibodies

News alert 📰 Exciting developments for the #Alchemab team as a peer-reviewed article has been published in Nature Immunology, Nature Portfolio, highlighting Alchemab's capabilities and potential to develop new #cancer therapies. In cancer, Alchemab focuses on identifying #antibodies from patients with certain solid tumors who are long-term survivors of the disease.   Find out more about Alchemab's preliminary work and identification of antibodies associated with checkpoint inhibition, angiogenesis, and cytokine modulation in cancer survivors in the press release linked in the comments.   #biotech #lifesciences #oncology Rachael Bashford-Rogers

#Alchemab's Senior Vice President of Research, Ralph Minter is in Cambridge for the FTD UK Annual Meeting on Wednesday 15th May! If you are attending, make sure to join Ralph's presentation at 2 pm BST as he explores 'Mining the immune system for protective antibodies in neurodegenerative diseases'. FTD UK, in its 11th year, brings together clinicians and researchers in the UK working on frontotemporal dementia and associated disorders. Look forward to networking with fellow attendees there! #biotech #lifesciences #neuroscience #antibodies #dementia #frontotemporaldementia